Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
23:16
General Matthew Jones warns that Russia’s aggression could trigger a miscalculation with serious consequences for NATO.
22:53
The French prosecutor's office is investigating several police officers accused of violence and sexual assault at a protest in Paris
22:30
Belgian air traffic controllers will go on strike on Monday, suspending flights at airports across the country
22:15
Donald Trump has identified Stephen Miller as a possible successor in the 2028 presidential election
22:00
Police in Dâmbovița are investigating the death of a caregiver found with signs of violence and the discovery of the elderly woman’s son, hanged.
See more news